Literature DB >> 31080020

Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis.

Kenchi Takenaka1, Tomoko Minami2, Yoko Yoshihashi2, Shinya Hirata3, Yoshitaka Kimura4, Hajime Kono4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31080020     DOI: 10.1016/j.alit.2019.04.006

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


× No keyword cloud information.
  5 in total

Review 1.  A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis.

Authors:  Haruki Koike; Ryoji Nishi; Satoru Yagi; Soma Furukawa; Yuki Fukami; Masahiro Iijima; Masahisa Katsuno
Journal:  Adv Ther       Date:  2022-09-24       Impact factor: 4.070

2.  Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis.

Authors:  Angelo Coppola; Krisstopher Richard Flores; Francesca De Filippis
Journal:  Respir Med Case Rep       Date:  2020-04-04

Review 3.  Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.

Authors:  Yasuhiko Koga; Haruka Aoki-Saito; Yosuke Kamide; Makiko Sato; Hiroaki Tsurumaki; Masakiyo Yatomi; Tamotsu Ishizuka; Takeshi Hisada
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

Review 4.  Eosinophilic airway diseases: basic science, clinical manifestations and future challenges.

Authors:  Christer Janson; Leif Bjermer; Lauri Lehtimäki; Hannu Kankaanranta; Jussi Karjalainen; Alan Altraja; Valentyna Yasinska; Bernt Aarli; Madeleine Rådinger; Johan Hellgren; Magnus Lofdahl; Peter H Howarth; Celeste Porsbjerg
Journal:  Eur Clin Respir J       Date:  2022-03-02

5.  Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab.

Authors:  Luisa Ricciardi; Daniel Griscti Soler; Alessandra Bennici; Silvia Brunetto; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Front Pharmacol       Date:  2022-04-07       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.